# Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

> **NCT06627179** · PHASE2 · RECRUITING · sponsor: **Laboratoires Thea** · enrollment: 81 (estimated)

## Conditions studied

- Retinitis Pigmentosa (RP)
- Usher Syndrome Type 2
- Deaf Blind
- Retinal Disease
- Eye Diseases, Hereditary
- Eye Disorders Congenital
- Vision Disorders

## Interventions

- **DRUG:** Intravitreal Injection of Ultevursen
- **OTHER:** No intervention, will not receive any active study intervention

## Key facts

- **NCT ID:** NCT06627179
- **Lead sponsor:** Laboratoires Thea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-11
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2026-03-30

## Collaborators

- Sepul Bio

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06627179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06627179, "Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06627179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*